Heat-shock proteins as powerful weapons in vaccine development

References

• Burdon RH. Heat shock and the heat shock proteins. Biochem. J.240, 313–324 (1986).
   PubMed Web of Science ®Google Scholar
• Pockley AG. Heat shock proteins as regulators of the immune response. Lancet362(9382), 469–476 (2003).
   PubMed Web of Science ®Google Scholar
• Mizzen L. Immune responses to stress proteins: applications to infectious disease and cancer. Biotherapy10, 173–189 (1998).
   PubMedGoogle Scholar
• Singh-Jasuja H, Hilf N, Arnold-Schild D, Schild H. The role of heat shock proteins and their receptors in the activation of the immune system. Biol. Chem.382, 629–636 (2001).
   PubMed Web of Science ®Google Scholar
• Guzhova I, Margulis B. Hsp70 chaperone as a survival factor in cell pathology. Int. Rev. Cytol.254, 101–149 (2006).
   PubMedGoogle Scholar
• Pockley AG. Heat shock proteins in health and disease: therapeutic targets or therapeutic agents? Expert Rev. Mol. Med.3, 1–21 (2001).
   PubMedGoogle Scholar
• Hu Y, Mivechi NF. HSF1 interacts with Ral binding protein 1 (RalBP1) in a stress-responsive multi-protein complex with HSP90 in vivo. J. Biol. Chem.278(19), 17299–17306 (2003).
   PubMed Web of Science ®Google Scholar
• Bagatell R, Paine-Murrieta GD, Taylor CW et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of Hsp90-binding agents. Clin. Cancer Res.6, 3312–3318 (2000).
   PubMed Web of Science ®Google Scholar
• Ali A, Bharadwaj S, O’Carroll R, Ovsenek N. HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. Mol. Cell. Biol.18(9), 4949–4960 (1998).
   PubMed Web of Science ®Google Scholar
• Bharadwaj S, Ali A, Ovsenek N. Multiple components of the HSP90 chaperone complex function in regulation of heat shock factor 1 in vivo. Mol. Cell. Biol.19(10), 8033–8041 (1999).
   PubMed Web of Science ®Google Scholar
• Eden W, Zee R, Prakken B. Heat-shock proteins induce T cell regulation of chronic inflammation. Nat. Rev. Immunol.5, 318–330 (2005).
   PubMed Web of Science ®Google Scholar
• Facciponte JG, Wang XY, MacDonald IJ et al. Heat shock proteins HSP70 and Gp96: structural insights. Cancer Immunol. Immunother.55, 339–346 (2006).
   PubMed Web of Science ®Google Scholar
• Robert J. Evolution of heat shock protein and immunity. Dev. Comp. Immunol.27, 449–464 (2003).
   PubMed Web of Science ®Google Scholar
• Ciupitu AM. Hsp70 in immunotherapy: a potential vector in cancer and viral vaccines. Stockholm (Thesis), 2000.
   Google Scholar
• Easton DP, Kaneko Y, Subjeck JR. The Hsp110 and Grp170 stress proteins: newly recognized relatives of the Hsp70s. Cell Stress Chaperones5(4), 276–290 (2000).
   PubMed Web of Science ®Google Scholar
• Fan CY, Lee S, Cyr DM. Mechanisms for regulation of Hsp70 function by Hsp40. Cell Stress Chaperones8(4), 309–316 (2003).
   PubMed Web of Science ®Google Scholar
• Yang Y, Li Z. Roles of heat shock protein gp96 in the ER quality control: redundant or unique function? Mol. Cells20(2), 173–182 (2005).
   PubMed Web of Science ®Google Scholar
• Meng SD, Song J, Rao Z, Tien P, Gao GF. Three-step purification of gp96 from human liver tumor tissues suitable for isolation of gp96-bound peptides. J. Immunol. Methods264, 29–35 (2002).
   PubMed Web of Science ®Google Scholar
• Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function and clinical applications: a comprehensive review. Pharmacol. Ther.79(2), 129–168 (1998).
   PubMed Web of Science ®Google Scholar
• Baker-LePain JC, Sarzotti M, Fields TA, Li CY, Nicchitta CV. GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue non-restricted tumor suppression. J. Exp. Med.196, 1447–1459 (2002).
   PubMed Web of Science ®Google Scholar
• Li H, Zhou M, Han J et al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J. Immunol.174, 195–204 (2005).
   PubMed Web of Science ®Google Scholar
• Linderoth NA, Popowicz A, Sastry S. Identification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen gp96 (Grp94). J. Biol. Chem.275(8), 5472–5477 (2000).
   PubMed Web of Science ®Google Scholar
• Soldano KL, Jivan A, Nicchitta CV, Gewirth DT. Structure of the N-terminal domain of GRP94. J. Biol. Chem.279(48), 48330–48338 (2003).
   Google Scholar
• Li Z, Srivastava PK. Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J.12(8), 3143–3151 (1993).
   PubMed Web of Science ®Google Scholar
• Menoret A, Li Z, Niswonger ML, Altmeyer A, Srivastava PK. An endoplasmic reticulum protein implicated in chaperoning peptides to major histocompatibility of class I is an aminopeptidase. J. Biol. Chem.276(36), 33313–33318 (2001).
   PubMed Web of Science ®Google Scholar
• Parmiani G, Testori A, Maio M et al. Heat shock proteins and their use as anticancer vaccines. Clin. Cancer Res.10, 8142–8146 (2004).
   PubMed Web of Science ®Google Scholar
• Li Z, Menoret A, Srivastava P. Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr. Opin. Immunol.14, 45–51 (2002).
   PubMed Web of Science ®Google Scholar
• Chen DX, Su YR, Shao GZ, Qian ZC. Purification of heat shock protein 70-associated tumor peptides and its anti-tumor immunity on hepatoma in mice. World J. Gastroenterol.10(3), 361–365 (2004).
   PubMed Web of Science ®Google Scholar
• Nicchitta CV, Carrick DM, Baker-LePain JC. The messenger and the message: gp96 (GRP94)–peptide interactions in cellular immunity. Cell Stress Chaperones9(4), 325–331(2004).
   PubMed Web of Science ®Google Scholar
• Blachere NE, Li Z, Chandawarkar RY et al. Heat shock protein–peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med.186(8), 1315–1322 (1997).
   PubMed Web of Science ®Google Scholar
• Singh-Jasuja H, Toes REM, Spee P et al. Cross-presentation of Gp96-associated antigens on MHC class I molecules requires receptor-mediated endocytosis. J. Exp. Med.191, 1965–1974 (2000).
   PubMed Web of Science ®Google Scholar
• Morales H, Muharemagic A, Gantress J, Cohen N, Robert J. Bacterial stimulation upregulates the surface expression of the stress protein gp96 on B cells in the frog Xenopus. Cell Stress Chaperones8(3), 265–271 (2003).
   PubMed Web of Science ®Google Scholar
• Robert J, Cohen N, Maniero GD, Goyos A, Morales H, Gantress J. Evolution of the immunomodulatory role of the heat shock protein gp96. Cell. Mol. Biol.49(2), 263–275 (2003).
   PubMed Web of Science ®Google Scholar
• Suriano R, Ghosh SK, Ashok BT et al. Differences in glycosylation patterns of heat shock protein, gp96: implications for prostate cancer prevention. Cancer Res.65, 6466–6475 (2005).
   PubMed Web of Science ®Google Scholar
• More S, Breloer M, Fleischer B, Bonin A. Activation of cytotoxic T cells in vitro by recombinant gp96 fusion proteins irrespective of the fused antigenic peptide sequence. Immunol. Lett.69(2), 275–282 (1999).
   PubMed Web of Science ®Google Scholar
• Baker-Lepain JC, Sarzotti M, Nicchitta CV. Glucose-regulated protein 94/ glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo. J. Immunol.172, 4195–4203 (2004).
   PubMed Web of Science ®Google Scholar
• Binder RJ, Srivastava PK. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc. Natl Acad. Sci. USA101(16), 6128–6133 (2004).
   PubMed Web of Science ®Google Scholar
• Stebbing J, Gazzard B, Kim L et al. The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected “true” long-term nonprogressors. Blood101(10), 4000–4004 (2003).
   PubMed Web of Science ®Google Scholar
• Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70 and calreticulin. Immunity14, 303–313 (2001).
   PubMed Web of Science ®Google Scholar
• Binder RJ, Karimeddini D, Srivastava PK. Adjuvanticity of α2-macroglobulin, an independent ligand for the heat shock protein receptor CD91. J. Immunol.166, 4968–4972 (2001).
   PubMed Web of Science ®Google Scholar
• Singh-Jasuja H, Scherer HU, Hilf N et al. The heat shock protein Gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol.30, 2211–2215 (2000).
   PubMed Web of Science ®Google Scholar
• Singh-Jasuja H, Hilf N, Scherer HU et al. The heat shock protein Gp96- a receptor- targeted cross-priming carrier and activator of dendritic cells. Cell Stress Chaperones5, 462–470 (2001).
   Web of Science ®Google Scholar
• Binder RJ, Vatner R, Srivastava P. The heat-shock protein receptors: some answers and more questions. Tissue Antigens64, 442–451 (2004).
   PubMedGoogle Scholar
• Demine R, Walden P. Testing the role of gp96 as peptide chaperone in antigen processing. J. Biol. Chem.280(18), 17573–17578 (2005).
   PubMed Web of Science ®Google Scholar
• Asea A. Chaperokine-induced signal transduction pathways. Exerc. Immunol. Rev.9, 25–33 (2003).
   PubMed Web of Science ®Google Scholar
• Asea A. Stress proteins and initiation of immune response: chaperokine activity of Hsp72. Exerc. Immunol. Rev.11, 34–45 (2005).
   PubMed Web of Science ®Google Scholar
• Warger T, Hilf N, Rechtsteiner G et al. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J. Biol. Chem.281(32), 22545–22553 (2006).
   PubMed Web of Science ®Google Scholar
• Segal BH, Wang XY, Dennis CG et al. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov.Today11(11/12), 534–540 (2006).
   PubMed Web of Science ®Google Scholar
• Rahman QK. Heat shock proteins as vaccine adjuvants. Stockholm (thesis), 2005.
   Google Scholar
• Wallin RPA, Lundqvist A, More SH, von Bonin A, Kiessling R, Ljunggren HG. Heat-shock proteins as activators of the innate immune system. Trends Immunol.23, 130–135 (2002).
   PubMed Web of Science ®Google Scholar
• Bendz H, Ruhland SC, Pandya MJ et al. Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling. J. Biol. Chem.282, 31688–31702 (2007).
   PubMed Web of Science ®Google Scholar
• Ye Z, Gan YH. Flagellin contamination of recombinant heat shock protein 70 is responsible for its activity on T cells. J. Biol. Chem.282(7), 4479–4484 (2007).
   PubMed Web of Science ®Google Scholar
• Chandawarkar RY, Wagh MS, Kovalchin JT, Srivastava P. Immune modulation with high-dose heat shock protein Gp96: therapy of murine autoimmune diabetes and encephalomyelitis. Int. Immunol.16(4), 615–624 (2004).
   PubMed Web of Science ®Google Scholar
• Radons J, Multhoff G. Immunostimulatory functions of membrane-bound and exported heat shock protein 70. Exerc. Immunol. Rev.11, 17–33 (2005).
   PubMed Web of Science ®Google Scholar
• Multhoff G. Heat shock proteins in immunity. Handb. Exp. Pharmacol.172, 279–304 (2006).
   Google Scholar
• Gross C, Hansch D, Gastpar R, Multhoff G. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol. Chem.384, 267–279 (2003).
   PubMed Web of Science ®Google Scholar
• Gross C, Koelch W, DeMaio A, Arispe N, Multhoff G. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J. Biol. Chem.278, 41173–41181 (2003).
   PubMed Web of Science ®Google Scholar
• Panjwani NN, Popova L, Srivastava PK. Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs. J. Immunol.168, 2997–3003 (2002).
   PubMed Web of Science ®Google Scholar
• Hauser H, Chen SY. Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods31, 225–231 (2003).
   PubMed Web of Science ®Google Scholar
• Hsu KF, Hung CF, Cheng WF et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosisheat shock protein 70 to an antigen. Gene Ther.8, 376–383 (2001).
   PubMed Web of Science ®Google Scholar
• Chen CH, Wang TL, Hung CF. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res.15, 1035–1042 (2000).
   Google Scholar
• Chu NR, Wu HB, Wu TC, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette–Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol.121, 216–225 (2000).
   PubMed Web of Science ®Google Scholar
• Huang CY, Chen CA, Lee CN. DNA vaccine encoding heat shock protein 60 co-linked to HPV-16E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Gynecol. Oncol.107(3), 404–412 (2007).
   PubMed Web of Science ®Google Scholar
• Rapp UK, Kaufmann SHE. DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int. Immunol.16(4), 597–605 (2004).
   PubMed Web of Science ®Google Scholar
• Reimann J, Schirmbeck R. DNA vaccines expressing antigens with a stress protein-capturing domain display enhanced immunogenicity. Immunol. Rev.199, 54–67 (2004).
   PubMed Web of Science ®Google Scholar
• Kim D, Gambhira R, Karanam B et al. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine26(3), 351–360 (2008).
   PubMed Web of Science ®Google Scholar
• Lowrie DB, Tascon RE, Bonato VL et al. Therapy of tuberculosis in mice by DNA vaccination. Nature400, 269–271 (1999).
   PubMed Web of Science ®Google Scholar
• Qazi KR, Wikman M, Vasconcelos NM, Berzins K, Stahl S, Fernandez C. Enhancement of DNA vaccine potency by linkage a Plasmodium falciparum malaria antigen gene fused with a fragment of HSP70 gene. Vaccine23(9), 1114–1125 (2005).
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Zahedifard F, Taghikhani M, Rafati S. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine26, 3362–3370 (2008).
   PubMed Web of Science ®Google Scholar
• Rafati S, Gholami E, Hassani N et al.Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine25, 4159–4169 (2007).
   PubMed Web of Science ®Google Scholar
• Larreta R, Soto M, Alonso C, Requena JM. Leishmania infantum: gene cloning of the GRP94 homologue, its expression as recombinant protein and analysis of antigenicity. Exp. Parasitol.96(2), 108–118 (2000).
   PubMed Web of Science ®Google Scholar
• Biswas C, Sriram U, Ciric B, Ostrovsky O, Gallucci S, Argon Y. The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen- presenting cells. Int. Immunol.18(7), 1147–1157 (2006).
   PubMed Web of Science ®Google Scholar
• Hilf N, Radsak M, Schild H. Host-derived adjuvants. In: Novel vaccination strategies.. Kaufmann SHE (Ed.). Weinheim, Germany, 129–145 (2004).
   Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol.5, 505–517 (2007).
   PubMed Web of Science ®Google Scholar
• Kumar S, Jones TR, Oakley MS et al. CpG oligodeoxynucleotide and montanide ISA51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect. Immun.72(2), 949–957 (2004).
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Haigwood NL. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods31, 207–216 (2003).
   PubMed Web of Science ®Google Scholar
• Hauser H, Shen L, Gu QL, Krueger S, Chen SY. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther.11(11), 924–932 (2004).
   PubMed Web of Science ®Google Scholar
• Rico AI, Sergio OA, Alonso C, Requena JM. Immunostimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83. Mol. Immunol.36, 1131–1139 (1999).
   PubMed Web of Science ®Google Scholar
• Rico AI, Del Real G, Soto M et al. Characterization of the immunostimulatory property of L. infantum HSP70 by fusion to the E. coli MBP in normal and nu/nu BALB/c mice. Infect. Immun.66(1), 347–352 (1998).
   PubMed Web of Science ®Google Scholar
• Skeiky YAW, Benson DR, Guderian JA et al. Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infection63, 4105–14 (1995).
   Web of Science ®Google Scholar
• Amorim AG, Cardoso de Almeida ML. Identification of the C-terminal region of 70 kDa heat shock protein from Leishmania (Viannia) braziliensis as a target for the human immune response. Cell Stress Chaperones1(3), 177–187 (1996).
   PubMed Web of Science ®Google Scholar
• Wallace GR, Ball AE, MacFarlane J, Safi SH, Miles MA, Kelly JM. Mapping of visceral leishmaniasis-specific immunodominant B-cell epitope of Leishmania donovani HSP70. Infect Immun.60, 2688–2693 (1992).
   PubMed Web of Science ®Google Scholar
• Costa SR, D’Oliveira A Jr, Bacellar O, Carvalho EM. T cell response of asymptomatic Leishmania chagasi infected subjects to recombinant Leishmania antigens. Mem. Inst. Oswaldo Cruz.94(3), 367–370 (1999).
   PubMedGoogle Scholar
• Arora SK, Kaur D, Sehgal S, Datta U. Identification of sero-specific epitope of recombinant heat shock protein (HSP70) of Leishmania donovani. J. Parasitic Dis.24(1), 21–26 (2000).
   Google Scholar
• Quijada L, Requena JM, Soto M, Alonso C. Analysis of the antigenic properties of the L. infantum HSP70: design of synthetic peptides for specific serodiagnosis of human leishmaniasis. Immunol. Lett.63, 169–174 (1998).
   PubMed Web of Science ®Google Scholar
• Mandic A, Vujkov T. Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann. Oncol.15, 197–200 (2004).
   PubMed Web of Science ®Google Scholar
• Lewis JJ. Therapeutic cancer vaccines: using unique antigens. Proc. Natl Acad. Sci. USA101(2), 14653–14656 (2004).
   PubMed Web of Science ®Google Scholar
• Qian X, Lu Y, Liu Q, Chen K, Zhao Q, Song J. Prophylactic, therapeutic and anti-metastatic effects of an HPV16mE6δ/mE7/TBhsp70δ fusion protein vaccine in an animal model. Immunol Lett.102(2), 191–201 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng WF, Hung CF, Chen CA et al. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine23(29), 3864–3874 (2005).
   PubMed Web of Science ®Google Scholar
• Liu B, Ye D, Song X et al. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent anti-tumor immunity and anti-angiogenesis. Vaccine26, 1387–1396 (2008).
   PubMed Web of Science ®Google Scholar
• Descoteaux A, Avila HA, Zhang K, Turco SJ, Beverley SM. Leishmania LPG3 encodes a GRP94 homolog required for phosphoglycan synthesis implicated in parasite virulence but not viability. EMBO J.21(17), 4458–4469 (2002).
   PubMed Web of Science ®Google Scholar
• Wang XY, Chen X, Manjili MH, Repasky E, Henderson R, Subjeck JR. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100. Cancer Res.63, 2553–2560 (2003).
   PubMed Web of Science ®Google Scholar
• Nardai G, Vegh E, Prohaszka Z, Csermely P. Chaperone-related immune dysfunction: an emergent property of distorted chaperone networks. Trends Immunol.27(2), 75–79 (2006).
   Google Scholar
• Zugel U, Kaufmann SHE. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin. Microbiol. Rev.12(1), 19–39 (1999).
   PubMed Web of Science ®Google Scholar
• Gaston JSH. Are heat shock proteins involved in autoimmunity? Int. J. Clin. Lab. Res.22(1–4), 90–94 (1992).
   PubMedGoogle Scholar